Report
Jehanne Leroy
EUR 1000.00 Purchase single report

Proxy Report 25/06/2018

Le conseil de Cerenis Therapeutics est désormais majoritairement indépendant (57%), ce dont nous félicitons la société. Par ailleurs, aucun administrateur ne cumule un nombre excessif de mandats et tous présentent des taux de présence supérieurs à 89% ; ainsi, Proxinvest soutient tous les renouvellements et nominations d'administrateurs proposés (résolutions 6 à 11).

Concernant la rémunération 2017 du Directeur Général, on regrettera que la société ne communique pas les taux de réalisation de chacun des critères du bonus 2017 puisque sans cette information, l'actionnaire ne peut pas comprendre comment le montant du bonus attribué au titre de 2017 a été déterminé. rappelons que Proxinvest avait annoncé dès début 2017 qu'en l'absence de cette information, une recommandation de vote négative serait systématiquement formulée.

Enfin, concernant les politiques de rémunération 2018 du Président et du Directeur Général, en l'absence de communication a minima des montants des rémunérations fixes qui seront attribuables, l'actionnaires ne peut pas déterminer les montants et structures potentiels sur lesquels il est appelé à voter. Ce manque d'information ne nous permet pas de soutenir les résolutions 16 et 17.

Underlying
Cerenis Therapeutics Holding SA

Cerenis Therapeutics Holding SA (Cerenis Therapeutics SA) is a France-based multinational biopharmaceutical company primarily engaged in the research, development and commercialization of High-density Lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. Cerenis Therapeutics Holding's product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The Company is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.

Provider
Proxinvest
Proxinvest

Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.

Proxinvest main services are :

  • ​Proxy reports
  • Definition and monitoring of client customized voting guidelines
  • Corporate Governance Data and Rating
  • Thematic research
  • Engagement support

Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.

Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.

As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide. 

Analysts
Jehanne Leroy

Other Reports on these Companies
Other Reports from Proxinvest
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch